NeoStem Brings Technology for Long-Term Storage of Adult Stem Cells
News Mar 26, 2007
Under NeoStem’s strategic business plan, the Company will provide stem cell collection and storage services through agreements with existing medical facilities around the country. The article spotlights one of the first of those facilities, the California Healthspan Institute, an anti-aging medical institute based in Encinitas, CA.
In addition to being one of the first NeoStem facilities, it is one of the first to provide adult stem cell extraction and long-term banking services.
Through the facility, health-conscious consumers; particularly those with a family history of serious illness such as cancer and heart disease; can pay a fee to have their own adult stem cells extracted and stored at the facility.
Scientists worldwide are working to develop new cures and therapies based on stem cell technology, with many focused on the use of so-called “autologous” stem cell therapies – or the use of a person’s own cells for their personal treatment.
“The use of autologous adult stem cells is thought to provide important advantages in both effectiveness and safety of any stem cell-based treatments ultimately developed and delivered to a patient,” said Dr. Robin Smith, NeoStem’s Chief Executive Officer.
“Planning ahead and storing the cells while still healthy is a form of “bio-insurance” that is gaining in popularity in the United States,” he continued.
The article can be viewed at http://www.trilogy-capital.com/tcp/neostem/sdbj.html.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.